Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy - Takeaways - MDSpire

Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy

  • By

  • Javier Cifuentes-Quin

  • Yiselle T. Garcia-Montañez

  • Alexandra Hurtado-Ortiz

  • Jhonatan Cruz

  • Luis Carlos Lagares

  • Luis A. Olarte-Licht

  • Maricel Licht-Ardila

  • Edgar Fabián Manrique-Hernández

  • May 22, 2026

  • 0 min

Share

  • 1

    Prostate cancer is the most commonly diagnosed malignancy among men in Colombia, highlighting a significant public health burden.

  • 2

    A study compared acute and late toxicity in prostate cancer patients treated with moderately hypofractionated versus ultra-hypofractionated radiotherapy.

  • 3

    Acute toxicity was significantly higher in the moderately hypofractionated group compared to the ultra-hypofractionated group (25.17% vs. 11.63%; p=0.013).

  • 4

    Late toxicity was also more frequent in the moderately hypofractionated group, with erectile dysfunction being the most common late event.

  • 5

    Ultra-hypofractionated radiotherapy demonstrated a favorable safety profile, associated with lower odds of acute toxicity compared to moderately hypofractionated radiotherapy.

Original Source(s)

Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy

  • by Javier Cifuentes-Quin, Yiselle T. Garcia-Montañez, Alexandra Hurtado-Ortiz, Jhonatan Cruz, Luis Carlos Lagares, Luis A. Olarte-Licht, Maricel Licht-Ardila, Edgar Fabián Manrique-Hernández

  • May 22, 2026

Related Content

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

The onco-functional reorganization of language network underlying metaplasticity induced by gliomas

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship